206 related articles for article (PubMed ID: 28991294)
1. Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer.
Pal K; Al-Suraih F; Gonzalez-Rodriguez R; Dutta SK; Wang E; Kwak HS; Caulfield TR; Coffer JL; Bhattacharya S
Nanoscale; 2017 Oct; 9(40):15622-15634. PubMed ID: 28991294
[TBL] [Abstract][Full Text] [Related]
2. Nanomechanical Insight of Pancreatic Cancer Cell Membrane during Receptor Mediated Endocytosis of Targeted Gold Nanoparticles.
Kulkarni T; Mukhopadhyay D; Bhattacharya S
ACS Appl Bio Mater; 2021 Jan; 4(1):984-994. PubMed ID: 34913031
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
[TBL] [Abstract][Full Text] [Related]
4. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
5. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.
Kelly KA; Bardeesy N; Anbazhagan R; Gurumurthy S; Berger J; Alencar H; Depinho RA; Mahmood U; Weissleder R
PLoS Med; 2008 Apr; 5(4):e85. PubMed ID: 18416599
[TBL] [Abstract][Full Text] [Related]
7. Dynamic alteration of poroelastic attributes as determinant membrane nanorheology for endocytosis of organ specific targeted gold nanoparticles.
Kulkarni T; Mukhopadhyay D; Bhattacharya S
J Nanobiotechnology; 2022 Feb; 20(1):74. PubMed ID: 35135558
[TBL] [Abstract][Full Text] [Related]
8. Optical magnetic multimodality imaging of plectin-1-targeted imaging agent for the precise detection of orthotopic pancreatic ductal adenocarcinoma in mice.
Zhang W; Liang X; Zhu L; Zhang X; Jin Z; Du Y; Tian J; Xue H
EBioMedicine; 2022 Jun; 80():104040. PubMed ID: 35525203
[TBL] [Abstract][Full Text] [Related]
9. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
10. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Elechalawar CK; Hossen MN; Shankarappa P; Peer CJ; Figg WD; Robertson JD; Bhattacharya R; Mukherjee P
Int J Nanomedicine; 2020; 15():991-1003. PubMed ID: 32103952
[TBL] [Abstract][Full Text] [Related]
11. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
12. Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer.
Wu Y; Tang Y; Xie S; Zheng X; Zhang S; Mao J; Wang B; Hou Y; Hu L; Chai K; Chen W
Theranostics; 2020; 10(3):1151-1165. PubMed ID: 31938057
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
14. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
[TBL] [Abstract][Full Text] [Related]
15. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
17. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
Smith RC; Bulanadi JC; Gill AJ; Rye KA; Hugh T; Proschogo N; Smith SF; Phillips L; Gong X; Julovi SM; Xue A; Moghaddam MJ
Cancer Lett; 2020 Dec; 495():112-122. PubMed ID: 32949679
[TBL] [Abstract][Full Text] [Related]
19. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Han H; Hou Y; Chen X; Zhang P; Kang M; Jin Q; Ji J; Gao M
J Am Chem Soc; 2020 Mar; 142(10):4944-4954. PubMed ID: 32069041
[TBL] [Abstract][Full Text] [Related]
20. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
